However, patients with genotype VNTR 3/3 had increased SMYD3 serum levels according to the progression of liver diseases (HCC vs. CHB: P = 0.0005, LC vs. CHB: P = 0.036, Fig. 2B). This evidence concerns the gene SMYD3 and hepatocellular carcinoma.